Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
56
IMTX Quote, Financials, Valuation and Earnings
Last price:
$10.10
Seasonality move
:
-0.36%
Day range:
$9.71 - $10.41
52-week range:
$3.30 - $12.41
Dividend yield:
0%
P/E ratio:
42.21x
P/S ratio:
13.76x
P/B ratio:
2.56x
Volume:
332K
Avg. volume:
375.8K
1-year change:
115.93%
Market cap:
$1.3B
Revenue:
$168.6M
EPS (TTM):
-$1.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMTX
Immatics NV
|
$10.9M | -$0.47 | -81.87% | -704.25% | $19.13 |
|
BAYRY
Bayer AG
|
$13.3B | $0.16 | 11.17% | 16.01% | $13.91 |
|
BNTX
BioNTech SE
|
$963.1M | -$0.10 | 93.93% | -31.18% | $139.76 |
|
CVAC
CureVac NV
|
$15.4M | -$0.11 | 0.04% | -32.36% | $5.31 |
|
IFRX
InflaRx NV
|
$30.9K | -$0.17 | -74.55% | -70.4% | $10.46 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMTX
Immatics NV
|
$10.30 | $19.13 | $1.3B | 42.21x | $0.00 | 0% | 13.76x |
|
BAYRY
Bayer AG
|
$13.28 | $13.91 | $52.2B | -- | $0.03 | 0.24% | 1.03x |
|
BNTX
BioNTech SE
|
$110.42 | $139.76 | $27.7B | 191.55x | $0.00 | 0% | 7.51x |
|
CVAC
CureVac NV
|
$4.66 | $5.31 | $1B | 6.52x | $0.00 | 0% | 12.94x |
|
IFRX
InflaRx NV
|
$0.87 | $10.46 | $59.1M | -- | $0.00 | 0% | 269.55x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMTX
Immatics NV
|
3.78% | 2.067 | 1.86% | 6.97x |
|
BAYRY
Bayer AG
|
57.27% | -0.191 | 142.34% | 0.55x |
|
BNTX
BioNTech SE
|
1.31% | 1.308 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 2.704 | 3.39% | 1.84x |
|
IFRX
InflaRx NV
|
2.1% | -0.262 | 1.26% | 2.34x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
BAYRY
Bayer AG
|
$6.3B | $655.6M | -0.4% | -0.91% | 5.81% | $616.1M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
Immatics NV vs. Competitors
-
Which has Higher Returns IMTX or BAYRY?
Bayer AG has a net margin of -974.45% compared to Immatics NV's net margin of -9.93%. Immatics NV's return on equity of -25.21% beat Bayer AG's return on equity of -0.91%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M BAYRYBayer AG55.41% -$0.29 $81.5B -
What do Analysts Say About IMTX or BAYRY?
Immatics NV has a consensus price target of $19.13, signalling upside risk potential of 85.68%. On the other hand Bayer AG has an analysts' consensus of $13.91 which suggests that it could grow by 4.76%. Given that Immatics NV has higher upside potential than Bayer AG, analysts believe Immatics NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 BAYRYBayer AG1 1 0 -
Is IMTX or BAYRY More Risky?
Immatics NV has a beta of 1.359, which suggesting that the stock is 35.865% more volatile than S&P 500. In comparison Bayer AG has a beta of 0.677, suggesting its less volatile than the S&P 500 by 32.328%.
-
Which is a Better Dividend Stock IMTX or BAYRY?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bayer AG offers a yield of 0.24% to investors and pays a quarterly dividend of $0.03 per share. Immatics NV pays -- of its earnings as a dividend. Bayer AG pays out 4.24% of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IMTX or BAYRY?
Immatics NV quarterly revenues are $6.1M, which are smaller than Bayer AG quarterly revenues of $11.3B. Immatics NV's net income of -$59.1M is higher than Bayer AG's net income of -$1.1B. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.76x versus 1.03x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.76x 42.21x $6.1M -$59.1M BAYRYBayer AG1.03x -- $11.3B -$1.1B
-
Which has Higher Returns IMTX or BNTX?
BioNTech SE has a net margin of -974.45% compared to Immatics NV's net margin of -1.89%. Immatics NV's return on equity of -25.21% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About IMTX or BNTX?
Immatics NV has a consensus price target of $19.13, signalling upside risk potential of 85.68%. On the other hand BioNTech SE has an analysts' consensus of $139.76 which suggests that it could grow by 26.57%. Given that Immatics NV has higher upside potential than BioNTech SE, analysts believe Immatics NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 BNTXBioNTech SE14 5 0 -
Is IMTX or BNTX More Risky?
Immatics NV has a beta of 1.359, which suggesting that the stock is 35.865% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.488, suggesting its more volatile than the S&P 500 by 48.755%.
-
Which is a Better Dividend Stock IMTX or BNTX?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or BNTX?
Immatics NV quarterly revenues are $6.1M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Immatics NV's net income of -$59.1M is lower than BioNTech SE's net income of -$33.5M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.76x versus 7.51x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.76x 42.21x $6.1M -$59.1M BNTXBioNTech SE7.51x 191.55x $1.8B -$33.5M
-
Which has Higher Returns IMTX or CVAC?
CureVac NV has a net margin of -974.45% compared to Immatics NV's net margin of -5832.47%. Immatics NV's return on equity of -25.21% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About IMTX or CVAC?
Immatics NV has a consensus price target of $19.13, signalling upside risk potential of 85.68%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 14.28%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 CVACCureVac NV1 3 0 -
Is IMTX or CVAC More Risky?
Immatics NV has a beta of 1.359, which suggesting that the stock is 35.865% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.877, suggesting its more volatile than the S&P 500 by 87.704%.
-
Which is a Better Dividend Stock IMTX or CVAC?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or CVAC?
Immatics NV quarterly revenues are $6.1M, which are smaller than CureVac NV quarterly revenues of $63.3M. Immatics NV's net income of -$59.1M is lower than CureVac NV's net income of $319.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while CureVac NV's PE ratio is 6.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.76x versus 12.94x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.76x 42.21x $6.1M -$59.1M CVACCureVac NV12.94x 6.52x $63.3M $319.3M
-
Which has Higher Returns IMTX or IFRX?
InflaRx NV has a net margin of -974.45% compared to Immatics NV's net margin of -51538.49%. Immatics NV's return on equity of -25.21% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About IMTX or IFRX?
Immatics NV has a consensus price target of $19.13, signalling upside risk potential of 85.68%. On the other hand InflaRx NV has an analysts' consensus of $10.46 which suggests that it could grow by 1098.21%. Given that InflaRx NV has higher upside potential than Immatics NV, analysts believe InflaRx NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 IFRXInflaRx NV5 2 0 -
Is IMTX or IFRX More Risky?
Immatics NV has a beta of 1.359, which suggesting that the stock is 35.865% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.457, suggesting its more volatile than the S&P 500 by 45.659%.
-
Which is a Better Dividend Stock IMTX or IFRX?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or IFRX?
Immatics NV quarterly revenues are $6.1M, which are larger than InflaRx NV quarterly revenues of $27.8K. Immatics NV's net income of -$59.1M is lower than InflaRx NV's net income of -$14.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.76x versus 269.55x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.76x 42.21x $6.1M -$59.1M IFRXInflaRx NV269.55x -- $27.8K -$14.3M
-
Which has Higher Returns IMTX or MDGEF?
Medigene AG has a net margin of -974.45% compared to Immatics NV's net margin of --. Immatics NV's return on equity of -25.21% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M MDGEFMedigene AG-- -- -- -
What do Analysts Say About IMTX or MDGEF?
Immatics NV has a consensus price target of $19.13, signalling upside risk potential of 85.68%. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Immatics NV has higher upside potential than Medigene AG, analysts believe Immatics NV is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 MDGEFMedigene AG0 0 0 -
Is IMTX or MDGEF More Risky?
Immatics NV has a beta of 1.359, which suggesting that the stock is 35.865% more volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IMTX or MDGEF?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or MDGEF?
Immatics NV quarterly revenues are $6.1M, which are larger than Medigene AG quarterly revenues of --. Immatics NV's net income of -$59.1M is higher than Medigene AG's net income of --. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.76x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.76x 42.21x $6.1M -$59.1M MDGEFMedigene AG-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 21
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
